Craft
  • Home
  •  / Atara Biotherapeutics
Atara Biotherapeutics

Atara Biotherapeutics

Phase III Trials Products

1

FY, 2016

Market Capitalization

$371.4 M

2022-11-21

Atara Biotherapeutics Summary

Company summary

Overview
Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Atara operates through the business of developing and commercializing therapeutics segment.
Type
Public
Status
Active
Founded
2012
HQ
South San Francisco, CA, US | view all locations
Website
http://atarabio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Pascal Touchon

    Pascal Touchon, President and Chief Executive Officer, Director

  • Eric Dobmeier
  • Roy D Baynes

    Roy D Baynes, Director

    • Ron Renaud

      Ron Renaud, Chairman of the Board

      Operating MetricsView all

      Phase III Trials Products

      1

      FY, 2016

      Phase II Trials Products

      3

      FY, 2016

      Phase I Trials Products

      3

      FY, 2016

      LocationsView all

      7 locations detected

      • South San Francisco, CA HQ

        United States

        Building 83, 611 Gateway Blvd #900

      • Aurora, CO

        United States

        12635 E Montview Blvd #280

      • New York, NY

        United States

        135 E 57th St 14th Floor

      • Thousand Oaks, CA

        United States

        2380 Conejo Spectrum St #200

      • Reykjavík

        Iceland

        Kalkofnsvegur 2

      • Mocejón, CM

        Spain

      and 1 others

      Atara Biotherapeutics Financials

      Summary financials

      Net income (Q3, 2022)
      ($84.1M)
      EBIT (Q3, 2022)
      ($84.6M)

      Footer menu